Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways

Simona Serioli1, Ludovico Agostini2,3, Alberto Pietrantoni4

  • 1Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25123 Brescia, Italy.

Insights

Aggressive pituitary neuroendocrine tumors (PitNETs) understanding has advanced via molecular biology. This review details pathways and potential precision medicine targets for these challenging tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Aggressive pituitary neuroendocrine tumors (PitNETs) present unique challenges in treatment.
  • Advances in molecular biology and bioinformatics offer new insights into tumorigenesis and potential therapeutic targets.

Approach:

  • A comprehensive literature review was conducted using PubMed, Scopus, and Web of Science.
  • English papers published between January 2004 and June 2023 were selected (n=254).
  • Key topics including epigenetic aspects, membrane proteins, metalloproteases, molecular pathways, PPRK, and the immune microenvironment were analyzed.

Key Points:

  • Identified essential genes, molecular pathways, and regulators in aggressive PitNETs.
  • Explored the role of the tumoral microenvironment in PitNET progression.
  • Highlighted potential precision medicine strategies and target therapies.

Conclusions:

  • Understanding the molecular mechanisms driving PitNET aggressiveness is crucial.
  • Preliminary data suggest promising target therapies, but further research and clinical trials are essential.
  • Precision medicine approaches hold potential for treating PitNETs refractory to traditional therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K